Preoperative irradiation of renal cell carcinoma

Rost, A; Brosig, W

doi:10.1016/0090-4295(77)90124-8

Cited by 14 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preoperative irradiation with doses of 20-40 Gy has been used to facilitate resection, to sterilise well-oxygenated peripheral extensions of the tumour that might be transected during nephrectomy, and to decrease the chance of dissemination at the time of nephrectomy. No advantage has been demonstrated in patients receiving preoperative irradiation with doses of 20-40 Gy with respect to overall survival (OS) or survival free from distant metastases (FFDM), although improvement in resectability has been noted [1][2][3][4][5][6].…”

Section: Kidneymentioning

confidence: 99%

“…La RT pre-operatoria con dosi da 20 a 40 Gy è stata utilizzata per facilitare la resezione, per sterilizzare i margini periferici ben ossigenati del tumore che potrebbero essere sezionati durante la nefrectomia, e per ridurre la possibilità di disseminazione al momento della nefrectomia. Nessun vantaggio è stato dimostrato nei pazienti sottoposti a RT pre-operatoria con dosi da 20 a 40 Gy per ciò che riguarda la sopravvivenza globale (SG) o sopravvivenza libera da metastasi a distanza (SLMD), sebbene sia stato notato un miglioramento della resecabilità [1][2][3][4][5][6].…”

Section: Reneunclassified

See 1 more Smart Citation

Radiation therapy in urinary cancer: state of the art and perspective

et al. 2008

View full text Add to dashboard Cite

Invasive urinary tumours are relatively rare, and their treatment may cause important changes in urinary, sexual and social functions. A systematic review of external radiation therapy studies in urinary cancers was performed. This synthesis of the literature is based on data from meta-analyses, randomised and prospective trials and retrospective studies. There are few controlled clinical trials using adjuvant or radical radiotherapy with or without chemotherapy in cancer of the kidney, ureter and urethra. There are several reports on multimodality treatment in invasive bladder cancer: intravesical surgery and neoadjuvant chemotherapy to radiotherapy or concomitant radiochemotherapy with organ preservation. The conclusions reached for renal cancer are controversial, and data on cancers of the urethra and ureter are few and inconclusive. Sufficient data now exist in the literature to demonstrate that conservative management with organ preservation is a valuable alternative to radical cystectomy, the traditional gold standard, in invasive bladder cancer.

show abstract

Section: Kidneymentioning

confidence: 99%